Kiniksa Pharmaceuticals

What Kiniksa Pharmaceuticals does

Kiniksa Pharmaceuticals International, plc is a commercial-stage biopharmaceutical company founded in 2015 and headquartered in Bermuda (incorporated in the UK), listed on NASDAQ under ticker KNSA. The company develops and commercializes immune-modulating therapies targeting inflammatory and autoimmune diseases with high unmet need, with a strategic focus on cardiovascular indications. Its core product is ARCALYST (rilonacept), an IL-1α and IL-1β inhibitor that became the first and only FDA-approved therapy for recurrent pericarditis in March 2021, also approved for CAPS and DIRA. The clinical pipeline includes KPL-387 (Phase 2/3 IL-1 receptor antagonist mAb for recurrent pericarditis), Mavrilimumab (Phase 1 GM-CSFRα mAb for rare cardiovascular diseases), and KPL-404 (Phase 2 anti-CD40 mAb for rheumatoid arthritis), while vixarelimab is licensed globally to Roche and Genentech.

Kiniksa operates a specialty pharmaceutical commercial model, generating 100% of revenue from ARCALYST product sales through specialty pharmacy distribution channels and a field sales organization targeting specialist physicians including cardiologists and rheumatologists. The company had 4,550+ prescribing physicians and an estimated ~18% penetration of the addressable recurrent pericarditis patient population as of year-end 2025. ARCALYST delivered $677.6M in FY2025 revenue (62% YoY growth) and $214.3M in Q1 2026 (56% YoY growth), with 2026 guidance raised to $930-$945M. The company turned profitable in 2025 ($59M net income vs. $43.2M net loss in 2024), holds $468.1M in cash with no debt, and supports its franchise through the Kiniksa OneConnect patient services program, the RESONANCE Patient Registry, and disease-awareness initiatives including a DTC television campaign launched in April 2026.

The business is supported by a senior leadership team with deep rare-disease commercialization experience — most notably CEO Sanj K. Patel, who previously built and sold Synageva to Alexion for $9.7B in 2015. Geographic reach includes the US, UK, Switzerland, and Asia Pacific (via a Huadong Medicine partnership for ARCALYST and mavrilimumab, excluding Japan). The company is rated No. 1 in its industry group on the IBD Relative Strength Rating (93) as of 2026, with a market capitalization of approximately $3.59B.

Name

Kiniksa Pharmaceuticals

Legal name

Kiniksa Pharmaceuticals International, plc

Website

https://kiniksa.com

Company type

Public

Founded year

2015

Operating status

Operating

Headcount range

251–500 employees

Short description

Kiniksa Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and commercializes immune-modulating therapies, anchored by ARCALYST — the first and only FDA-approved treatment for recurrent pericarditis — serving patients with inflammatory and autoimmune diseases.

Ownership category

akta.pro rank

Product category

Specialty Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Rare Cardiovascular & Vascular Disorder Therapies (HLAIAIAH)

akta.pro secondary industry

Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG)

Keywords

• Biopharmaceutical therapies
• IL-1 pathway inhibition
• Recurrent pericarditis treatment
• Orphan drug development
• Autoimmune disease therapies

Headquarters

HQ city

Hamilton

HQ country

Bermuda

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

1. ARCALYST Product Sales: Commercial drug sales from ARCALYST (rilonacept), FDA-approved therapy for recurrent pericarditis, CAPS, and DIRA. Company generates 100% of revenue from this single drug.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

Core offering

Kiniksa Pharmaceuticals is a commercial-stage biopharmaceutical company that develops, manufactures, and commercializes immune-modulating therapies for inflammatory and autoimmune diseases. Its commercial product, ARCALYST (rilonacept), is an IL-1α and IL-1β inhibitor and the first and only FDA-approved therapy for recurrent pericarditis, also approved for CAPS and DIRA. The company also maintains a clinical-stage pipeline including KPL-387, mavrilimumab, KPL-404, and vixarelimab targeting serious diseases with unmet medical needs with a focus on cardiovascular indications.

Product overview

Kiniksa Pharmaceuticals is a commercial-stage biopharmaceutical company with an FDA-approved therapy and clinical-stage pipeline targeting serious diseases with unmet medical needs, focused on cardiovascular indications. The core product is ARCALYST (rilonacept), an IL-1α and IL-1β inhibitor approved for recurrent pericarditis, CAPS, and DIRA. The pipeline includes KPL-387 (Phase 2/3 for recurrent pericarditis), Mavrilimumab (Phase 1 for rare cardiovascular diseases), KPL-404 (Phase 2 for rheumatoid arthritis), and Vixarelimab (Roche/Genentech global rights). Patient support is provided through Kiniksa OneConnect program, and research efforts are supported by the RESONANCE patient registry.

Differentiator

Problem solved

Functional benefit

Brands

• ARCALYST: FDA-approved therapy for recurrent pericarditis, CAPS, and DIRA. IL-1α and IL-1β inhibitor.
• Kiniksa OneConnect

Products and services

• ARCALYST (rilonacept) FDA-approved IL-1α and IL-1β inhibitor for recurrent pericarditis, cryopyrin-associated periodic syndromes (CAPS), and deficiency of interleukin-1 receptor antagonist (DIRA). The therapy addresses inflammatory conditions through IL-1 pathway inhibition, representing the first and only FDA-approved therapy for recurrent pericarditis in adults and pediatric patients 12 years and older.
• KPL-387 Investigational monoclonal antibody IL-1 receptor antagonist in liquid formulation with once-monthly subcutaneous dosing target profile for recurrent pericarditis treatment. Currently in Phase 2/3 clinical development (KPL-387-C211 trial). Efficacy and safety have not been evaluated by any regulatory authority.
• Mavrilimumab GM-CSFRα targeting agent in Phase 1 development evaluating rare cardiovascular diseases. Kiniksa holds worldwide rights excluding Middle East and North Africa.
• KPL-404 (Abiprubart) Anti-CD40 monoclonal antibody in Phase 2 development for rheumatoid arthritis. Worldwide rights held by Kiniksa.
• Vixarelimab OSMRβ targeting antibody previously licensed through global license agreement. Global rights held by Roche and Genentech for all indications; Kiniksa no longer commercializes this asset.
• Kiniksa OneConnect Patient support program providing personalized one-on-one support throughout the treatment journey, including financial assistance options for patients with recurrent pericarditis, CAPS, and DIRA.
• RESONANCE Patient Registry Voluntary patient-powered registry and network of physicians and researchers dedicated to advancing research efforts in recurrent pericarditis.

Quantifiable outcome

• 56% year-over-year revenue growth in Q1 2026
• +3 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered global and regional.

• Roche and GenentechglobalStrategic or Co-development Partner · 1 July 2022Global license agreement with Roche and Genentech for rights to develop and commercialize vixarelinmab. Roche and Genentech hold global rights for all indications.
• Huadong MedicineregionalStrategic or Co-development Partner · 1 January 2022Strategic collaboration to develop and commercialize ARCALYST (rilonacept) and mavrilimumab in the Asia Pacific Region, excluding Japan. Huadong Medicine holds exclusive rights in this territory.

Scale indicators11 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• BioMarin Pharmaceutical: BioMarin is a larger rare-disease specialty biopharma with multiple Orphan Drug therapies. While broader than Kiniksa, BioMarin represents a relevant comparable for specialty pharma commercial scaling and pipeline diversification.
• Regeneron Pharmaceuticals: Regeneron is the original developer of rilonacept (ARCALYST) and licenses the trademark to Kiniksa. It is a broad incumbent in IL-1/inflammation biologics with Dupixent and other franchises, providing both competitive overlap and a strategic relationship with Kiniksa.
• Vertex Pharmaceuticals: Vertex is a broad specialty biopharma with rare disease franchises (CF, sickle cell) and a track record of converting rare disease leadership into a multi-billion-dollar franchise, providing a relevant comparable for Kiniksa's longer-term scaling potential.

Emerging players

• Apellis Pharmaceuticals: Apellis commercializes rare autoimmune ophthalmology therapies (Empaveli, Syfovre) using specialty pharmacy channels and rare-disease commercial infrastructure, with a similar growth profile and prescriber specialization.
• ChemoCentryx: ChemoCentryx (acquired by Amgen in 2022) was a rare autoimmune biopharma with Taveglin for ANCA-associated vasculitis, sharing Kiniksa's IL-pathway inflammation focus and orphan/specialty commercial approach.

Direct peers

• Corcept Therapeutics: Corcept is a specialty biopharma built around a single commercialized therapy (Korlym) with a focused sales force targeting specialist physicians, mirroring Kiniksa's orphan/specialty model and revenue trajectory.
• Madrigal Pharmaceuticals: Madrigal is a commercial-stage specialty biopharma that recently launched Rezdiffra, with comparable growth acceleration and specialty physician targeting. Both companies share a similar inflection from clinical-stage to commercial specialty pharma.
• Swedish Orphan Biovitrum (Sobi): Sobi markets Kineret (anakinra), an IL-1 receptor antagonist, and is a major rare-disease specialty biopharma. Sobi competes directly in IL-1 biology for inflammatory conditions and shares Kiniksa's orphan/specialty commercial model.
• Ultragenyx Pharmaceutical: Ultragenyx is a rare-disease commercial biopharma with multiple Orphan Drug-designated therapies and a focus on genetically defined conditions, comparable to Kiniksa's orphan/specialty strategy and pipeline depth.
• Travere Therapeutics: Travere is a rare-disease specialty biopharma with commercial products and pipeline assets in nephrology and rare metabolic conditions, comparable in patient population targeting, regulatory strategy (Orphan Drug), and commercial-stage evolution.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UC2X7vLPwYXPjzRa10OJuIaA
• LinkedInlinkedin.com/company/kiniksa-pharmaceuticals
• Xx.com/kiniksa

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds4 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kiniksa Pharmaceuticals